In Vivo Transfection Reagents

In Vivo Transfection Reagent (NANOPARTICLE-based)

LIPID-based In Vivo Transfection Reagent

Catalog # 5010 - 0.5 mL (10 injections) $ 405.00 Catalog # 5011 - 1.5 mL (30 injections) $ 895.00 siRNA and plasmid DNA in vivo delivery reagent Modes of administration: Systemic intravenous (i.v.) injection Direct intratumoral (i.t.) injection Intraperitoneal (i.p.) injection Altogen's In Vivo Transfection Reagent Cationic lipid liposome-based reagent Lipid conjugated complexes are stable in serum for 16h Efficient delivery to the liver, pancreas, kidney, and certain tumor types via systemic administration Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (various tumor types) Minimal toxicity Functionally tested in mice Applicable for plasmid DNA/siRNA co-injection Transfection protocols are provided with the purchase of the reagent Developed and manufactured by Altogen Biosystems

DATA

Figure 1. Systemic administration (i.v.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 2. Intratumoral administration (i.t.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

 

POLYMER-based In Vivo Transfection Reagent

Catalog # 5020 - 0.5 mL (10 injections) $ 425.00 Catalog # 5021 - 1.5 mL (30 injections) $ 935.00 siRNA and plasmid DNA in vivo delivery reagent Modes of administration: Systemic intravenous (i.v.) injection Direct intratumoral (i.t.) injection Altogen's In Vivo Transfection Reagent Biodegradable polymer-based In Vivo reagent No detectable inflammatory response Efficient delivery to the lung, liver, kidney, and spleen via systemic administration Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (multiple tumor types) Functionally tested in mice Applicable for plasmid DNA/siRNA co-injection Transfection protocols are provided with the purchase of the reagent Developed and manufactured by Altogen Biosystems

DATA

Figure 3. Systemic administration (i.v.) of Polymer-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 4. Intratumoral administration (i.t.) of Polymer-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

NANOPARTICLE-based In Vivo Transfection Reagent

Catalog # 5030 - 0.5 mL (10 injections) $ 445.00 Catalog # 5031 - 1.5 mL (30 injections) $ 955.00 siRNA and plasmid DNA in vivo delivery reagent Modes of administration: Systemic intravenous (i.v.) injection Direct intratumoral (i.t.) injection Altogen's In Vivo Transfection Reagent Nanoparticle-based reagent Complexes are stable in serum for 16h Efficient delivery to the heart, lung, liver, pancreas, kidney, and multiple tumor types via systemic administration Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (various tumor types) Minimal toxicity Functionally tested in mice Applicable for plasmid DNA/siRNA co-injection Transfection protocols are provided with the purchase of the reagent Developed and manufactured by Altogen Biosystems

DATA

Figure 5. Systemic administration (i.v.) of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 6. Intratumoral administration (i.t.) of Nanoparticle-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

PEG-Liposome based In Vivo Transfection Reagent

Catalog # 5040 - 0.5 mL (10 injections) $ 465.00 Catalog # 5041 - 1.5 mL (30 injections) $ 975.00 siRNA, DNA, and protein in vivo delivery reagent Modes of administration: Systemic intravenous (i.v.) injection Direct intratumoral (i.t.) injection Altogen's In Vivo Transfection Reagent PEGylated liposome based reagent No detectable toxicity or inflammatory response due to biodegradable PEG modification Complexes are stable in serum for at least 16h Efficient delivery to the spleen, kidney, pancreas, liver, and multiple tumor types via systemic administration Efficient delivery of negatively charged molecules including siRNA (shRNA, microRNA), plasmid DNA, and protein Functionally tested in mice Applicable for plasmid DNA/siRNA(shRNA) co-injection Transfection protocols are provided with the purchase of the reagent Developed and manufactured by Altogen Biosystems

DATA

Figure 7. Systemic administration (i.v.) of Liposome-PEG based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 8. Intratumoral administration (i.t.) of Liposome-PEG based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Altogen Research Services

Altogen Custom Services provide specialized biotechnology and pharmaceutical services, including - generation of stable cell lines, RNA Interference (RNAi) services, assay development, screening and transfection services. Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Altogen Services offers generation of stable cell lines by transforming the cell line of choice to stably express gene of interest or shRNA-encoding construct. Cloning and shRNA expression services are available.

Transfection Resource

siRNA Transfection || Transfection Methods || Stable Transfection || RNAi || siRNA Library Screening || RNAi Therapeutics || Cell Transfection || In Vivo Transfection Reagents || Cell Line Specific Transfection Reagents